3-Formyl-4-methylbenzoic acid → N-((S)-3-{2-ethyl-4-[5-(3-formyl-4-methyl-phenyl)-[1,2,4]oxadiazol-3-yl]-6-methyl-phenoxy}-2-hydroxy-propyl)-2-hydroxy-acetamide
Reaction equation
C(C1C=C(C2ON=C(C3C=C(C)C(OCC(O)CNC(=O)CO)=C(C)C=3)N=2)C=CC=1)=O.[CH:32]([C:34]1[CH:35]=[C:36]([CH:40]=[CH:41][C:42]=1[CH3:43])[C:37]([OH:39])=O)=[O:33].[CH2:44]([C:46]1[CH:61]=[C:60]([C:62](=[NH:65])[NH:63]O)[CH:59]=[C:58]([CH3:66])[C:47]=1[O:48][CH2:49][C@@H:50]([OH:57])[CH2:51][NH:52][C:53](=[O:56])[CH2:54][OH:55])[CH3:45]>>[CH2:44]([C:46]1[CH:61]=[C:60]([C:62]2[N:65]=[C:37]([C:36]3[CH:40]=[CH:41][C:42]([CH3:43])=[C:34]([CH:32]=[O:33])[CH:35]=3)[O:39][N:63]=2)[CH:59]=[C:58]([CH3:66])[C:47]=1[O:48][CH2:49][C@@H:50]([OH:57])[CH2:51][NH:52][C:53](=[O:56])[CH2:54][OH:55])[CH3:45]Participants
Procedure
The title compound (405 mg) is prepared in analogy to rac-N-(3-{4-[5-(3-formyl-phenyl)-[1,2,4]oxadiazol-3-yl]-2,6-dimethyl-phenoxy}-2-hydroxy-propyl)-2-hydroxy-acetamide, starting from 3-formyl-4-methyl-benzoic acid (338 mg, 2.06 mmol) and N—((S)-3-[2-ethyl-4-(N-hydroxycarbamimidoyl)-6-methyl-phenoxy]-2-hydroxy-propyl)-2-hydroxy-acetamide (670 mg, 2.06 mmol). LC-MS**: tR=0.68 min; [M+1]+=454.17; 1H NMR (D6-DMSO): δ 1.23 (t, J=7.5 Hz, 3H), 2.35 (s, 3H), 2.70-2.78 (m, 5H), 3.21-3.29 (m, 1H), 3.39-3.48 (m, 1H), 3.71-3.80 (m, 2H), 3.84 (d, J=5.5 Hz, 2H), 3.93-4.01 (m, 1H), 5.32 (d, J=5.3 Hz, 1H), 5.56 (t, J=5.5 Hz, 1H), 7.66 (d, J=8.3 Hz, 1H), 7.71 (t, J=5.5 Hz, 1H), 7.81 (s, 2H), 8.33 (dd, J=8.0, 1.8 Hz, 1H), 8.60 (d, J=1.8 Hz, 1H), 10.37 (s, 1H).
Sources & evidence
- ORD record
- ord-5c8982b90d304cb8b8e9c630061b7496
- Source dataset
- uspto-grants-2013_04
- Patent number
- US08410151B2
Reaction notes
Loading…